placenta-or palatine tonsil-derived MSCs (CP-MSCs) and even some differences exist, 1 comparable effects were observed [18, 19] . 2
ASCs and MSCs exhibit cell specific differences at transcriptional and proteomic levels as 3 well as functional differences in their differentiation processes towards adipocytes, 4 osteoblasts and chondrocytes [20] . MSCs demonstrate higher differentiation potential toward 5 chondrogenic and osteoblastic lineages whereas ASCs possess a better capacity to 6 differentiate into adipocytes [21, 22] . The best strategy for MSC-based therapy has therefore 7 to be determined according to their distinct characteristics associated with their tissue origin 8 for a particular therapeutic application. 9 10 3. Secretome-based therapeutic efficacy of mesenchymal stem cells for rheumatic 11 diseases 12 
13
The therapeutic value of BM-MSCs or ASCs for rheumatic diseases including osteoarthritis 14 (OA) and rheumatoid arthritis (RA) has been evaluated during the last few years. Because the 15 interest of using MSCs for cartilage tissue engineering has been reviewed elsewhere [9] , we 16 will focus here on the paracrine effect of MSCs for preventing cartilage degradation or 17 stimulating endogenous cartilage regeneration. Focusing on rheumatic diseases, it is likely 18 that the route of MSC administration will differ according to the pathology. In case of 19 systemic disease, such as rheumatoid arthritis (RA) where several joints may be affected, 20
systemic delivery via the bloodstream should be favored. On the contrary, for lesions that are 21 limited to a single joint, local delivery should be preferred because of better availability of 22 cells and safety. 23 The rationale for using local injection of MSCs for inducing regeneration of OA cartilage is 1 based on a number of in vitro studies, when MSCs and chondrocytes are mixed in pellet-or 2 alginate-based co-cultures [23] [24] [25] . Whatever the source of MSCs (BM, adipose tissue 
